Lexeo appoints COO and CMO; Eric Adler leaves to lead spin-off Myoventive

Lexeo Therapeutics, Inc.

Jose Manuel Otero, former CTO, becomes COO effective Jan 2, 2026; base salary set at $510,000.
Narinder P. Bhalla appointed Chief Medical Officer effective Jan 20, 2026, succeeding Eric Adler.
Eric Adler steps down as executive officer to become CEO of Myoventive, co-founded by Lexeo, Perceptive Xontogeny, and venBio Partners.
Adler remains senior clinical and scientific advisor to Lexeo.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.